MYAGIOS® PATIENT SUPPORT SERVICES

myAgios® Patient Support Services for PK Deficiency

Single point of engagement for prescription and access support

Centralized enrollment for eligible patients, including prescription fulfillment, financial assistance, access, and adherence support.

Access and Benefits Investigation Services

  • Support with insurance coverage
  • Administer patient assistance programs

Access and Benefits Investigation Services

  • Support with insurance coverage
  • Administer patient assistance programs

Prescription fulfillment through exclusive specialty pharmacy

  • Commercial product dispensing
  • Guidance with dosing questions and coordination of refills

Prescription fulfillment through exclusive specialty pharmacy

  • Commercial product dispensing
  • Guidance with dosing questions and coordination of refills

Dedicated and clinically experienced Patient Support Managers can offer

  • Single point of contact for HCPs and office staff to help patients access program offerings
  • Educational resources and information to help patients explore financial assistance

Dedicated and clinically experienced Patient Support Managers can offer

  • Single point of contact for HCPs and office staff to help patients access program offerings
  • Educational resources and information to help patients explore financial assistance

Prescribe PYRUKYND® in 3 steps

1. Download the enrollment form

Download Enrollment Form Download ANNOTATED Enrollment Form

2. Fax the form to myAgios at
1-800-951-7814

3. A dedicated myAgios Patient Support Manager (PSM) will reach out to your office staff and patients directly to support them throughout the treatment process

Financial Assistance Options and Coverage Support

Financial Assistance Options and Coverage Support

myAgios can connect patients to financial assistance and coverage support programs to help with access to PYRUKYND, including information about:

The PYRUKYND Copay Program

  • This program lowers costs for eligible patients to $0 per prescription if their copay exceeds that amount
  • Patients participating in government healthcare insurance are not eligible

The PYRUKYND Copay Program

  • This program lowers costs for eligible patients to $0 per prescription if their copay exceeds that amount
  • Patients participating in government healthcare insurance are not eligible

The Patient Assistance Program (PAP)

  • Offers free prescriptions to eligible uninsured and underinsured patients

The Patient Assistance Program (PAP)

  • Offers free prescriptions to eligible uninsured and underinsured patients

To learn more about a patient’s potential eligibility, start by calling myAgios at 1-800-951-3889.

Coverage Interruption Program

  • This program offers a free 28-day prescription (allowing 2 refills) for eligible commercially insured patients experiencing a temporary loss or gap in coverage
  • For eligible commercially insured patients who have filled at least one previous prescription of PYRUKYND and who experience a temporary loss or change in coverage
  • Patients participating in government healthcare insurance are not eligible

Coverage Interruption Program

  • This program offers a free 28-day prescription (allowing 2 refills) for eligible commercially insured patients experiencing a temporary loss or gap in coverage
  • For eligible commercially insured patients who have filled at least one previous prescription of PYRUKYND and who experience a temporary loss or change in coverage
  • Patients participating in government healthcare insurance are not eligible

Additional Coverage Options

Other forms of assistance may be available, including assistance from independent foundations for patients with government and commercial insurance. myAgios can provide a referral to one of these foundations. Eligibility is determined by the individual foundation. Agios is not affiliated with these organizations.

Please see full Terms and Conditions for more information on each program.

Agios’ experienced and dedicated PSMs can offer assistance for patients

Agios’ experienced and dedicated PSMs can offer assistance for patients

Who are the PSMs and what is their role?
PSMs:

  • Have over 30 years of collective experience with rare diseases
  • Tailor support for patients and their caregivers based upon their unique needs in living with PK deficiency
  • Can direct patients to educational resources about PYRUKYND and PK deficiency, including community connections
  • Help patients navigate financial assistance questions and eligibility criteria
  • Can be supportive resources and provide assistance through

— Regular phone calls (cadence is approximately monthly)

— Email communications

— Social support via patient webinars with other patients with PK deficiency

When a patient is prescribed PYRUKYND and the enrollment form is faxed to myAgios, the process for support can begin. HIPAA consent must be obtained to complete enrollment into the myAgios program.

This program is not intended as medical advice and patients should consult their healthcare team with questions related to their treatment.

PK=pyruvate kinase.

Learn more about myAgios Patient Support Services

Learn more

Indication

PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

Important Safety Information

Acute Hemolysis: Acute hemolysis with subsequent anemia has been observed following abrupt interruption or discontinuation of PYRUKYND in a dose-ranging study. Avoid abruptly discontinuing PYRUKYND. Gradually taper the dose of PYRUKYND to discontinue treatment if possible. When discontinuing treatment, monitor patients for signs of acute hemolysis and anemia including jaundice, scleral icterus, dark urine, dizziness, confusion, fatigue, or shortness of breath.

Adverse Reactions: Serious adverse reactions occurred in 10% of patients receiving PYRUKYND in the ACTIVATE trial, including atrial fibrillation, gastroenteritis, rib fracture, and musculoskeletal pain, each of which occurred in 1 patient. In the ACTIVATE trial, the most common adverse reactions including laboratory abnormalities (≥10%) in patients with PK deficiency were estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia.

Drug Interactions:

  • Strong CYP3A Inhibitors and Inducers: Avoid concomitant use.
  • Moderate CYP3A Inhibitors: Do not titrate PYRUKYND beyond 20 mg twice daily.
  • Moderate CYP3A Inducers: Consider alternatives that are not moderate inducers. If there are no alternatives, adjust PYRUKYND dosage.
  • Sensitive CYP3A, CYP2B6, CYP2C Substrates Including Hormonal Contraceptives: Avoid concomitant use with substrates that have narrow therapeutic index.
  • UGT1A1 Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.
  • P-gp Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.

Hepatic Impairment: Avoid use of PYRUKYND in patients with moderate and severe hepatic impairment.

Please see full Prescribing Information for PYRUKYND.

Indication

PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

Important Safety Information

Acute Hemolysis: Acute hemolysis with subsequent anemia has been observed
following abrupt interruption or discontinuation of PYRUKYND in a dose-ranging study. Avoid abruptly discontinuing PYRUKYND. Gradually taper the dose of PYRUKYND to discontinue treatment if possible. When discontinuing treatment, monitor patients for signs of acute hemolysis and anemia including jaundice, scleral icterus, dark urine, dizziness, confusion, fatigue, or shortness of breath.

Indication

PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

Important Safety Information

Acute Hemolysis: Acute hemolysis with subsequent anemia has been observed following abrupt interruption or discontinuation of PYRUKYND in a dose-ranging study. Avoid abruptly discontinuing PYRUKYND. Gradually taper the dose of PYRUKYND to discontinue treatment if possible. When discontinuing treatment, monitor patients for signs of acute hemolysis and anemia including jaundice, scleral icterus, dark urine, dizziness, confusion, fatigue, or shortness of breath.

Adverse Reactions: Serious adverse reactions occurred in 10% of patients receiving PYRUKYND in the ACTIVATE trial, including atrial fibrillation, gastroenteritis, rib fracture, and musculoskeletal pain, each of which occurred in 1 patient. In the ACTIVATE trial, the most common adverse reactions including laboratory abnormalities (≥10%) in patients with PK deficiency were estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia.

Drug Interactions:

  • Strong CYP3A Inhibitors and Inducers: Avoid concomitant use.
  • Moderate CYP3A Inhibitors: Do not titrate PYRUKYND beyond 20 mg twice daily.
  • Moderate CYP3A Inducers: Consider alternatives that are not moderate inducers. If there are no alternatives, adjust PYRUKYND dosage.
  • Sensitive CYP3A, CYP2B6, CYP2C Substrates Including Hormonal Contraceptives: Avoid concomitant use with substrates that have narrow therapeutic index.
  • UGT1A1 Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.
  • P-gp Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.

Hepatic Impairment: Avoid use of PYRUKYND in patients with moderate and severe hepatic impairment.

Please see full Prescribing Information for PYRUKYND.

Open ISI Close ISI